Possible factors affecting thyroid dysfunction in hepatitis C virus‑infected untreated patients

Mao,Xiao‑Rong; Zhang,Li‑Ting; Chen,Hong; Xiao,Ping; Zhang,You‑Cheng

doi:10.3892/etm.2014.1709

July-2014 Volume 8 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2014 Volume 8 Issue 1

Full Size Image

Article

Possible factors affecting thyroid dysfunction in hepatitis C virus‑infected untreated patients

Authors:
- Xiao‑Rong Mao
- Li‑Ting Zhang
- Hong Chen
- Ping Xiao
- You‑Cheng Zhang
View Affiliations / Copyright

Affiliations: Department of Infectious Diseases, The First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Department of General Surgery, The Second Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China
Pages: 133-140
|
Published online on: May 14, 2014

https://doi.org/10.3892/etm.2014.1709
Expand metrics +

Abstract

The present study investigated the association of thyroid dysfunction (TD) with the distribution of chronic hepatitis C virus (HCV) infection in untreated patients. A total of 1,012 cases of HCV‑infected patients were collected from different regions, of which 209 patients demonstrated a type of TD (chronic thyroiditis complicated with hyperthyroidism, chronic thyroiditis complicated with hypothyroidism, subclinical hyperthyroidism, subclinical hypothyroidism, hyperthyroidism, hypothyroidism or chronic thyroiditis). The results showed the existence of geographical differences in the types of TD present with HCV infection. The female patients had a higher incidence of autoimmune‑related TD than the male patients. High levels of HCV RNA expression were most common in all HCV‑infected patients, regardless of the presence of TD. High and medium expression levels of HCV RNA were more prevalent in the patients with autoimmune‑related TD. Relative analysis of the HCV RNA levels showed that the pathogenesis of TD was not correlated with the HCV RNA expression levels; however, it may have been associated with autoimmunity. The HCV‑infected patients with TD were most commonly middle‑aged, whereas young adults were the largest group of patients with HCV and normal thyroid function. Among all HCV genotypes, type 1b was the most common HCV genotype and type 2 was the second most common. Types 3 and 6 were scarce in this study population. No associations were identified between HCV genotypes and thyroid disease. The data of liver function showed that HCV‑infected patients with TD had a higher liver dysfunction rate compared with that of the patients with normal thyroid function. Therefore, liver dysfunction may be associated with thyroid disease. This study supports the potential of individualized treatment for HCV‑infected patients.

View Figures

View References

1	Cui Y and Jia J: Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 28(Suppl 1): 7–10. 2013. View Article : Google Scholar : PubMed/NCBI
2	Lauer GM and Walker BD: Hepatitis C virus infection. N Engl J Med. 345:41–52. 2001. View Article : Google Scholar : PubMed/NCBI
3	El-Serag HB, Hampel H, Yeh C and Rabeneck L: Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 36:1439–1445. 2002. View Article : Google Scholar : PubMed/NCBI
4	Andrade LJ, Atta AM, D’Almeida Junior A and Paraná R: Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin - a review. Braz J Infect Dis. 12:144–148. 2008. View Article : Google Scholar : PubMed/NCBI
5	Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M and Ferrannini E: Thyroid disorders in chronic hepatitis C virus infection. Thyroid. 16:563–572. 2006. View Article : Google Scholar : PubMed/NCBI
6	Tomer Y, Blackard JT and Akeno N: Interferon alpha treatment and thyroid dysfunction. Endocrinol Metab Clin North Am. 36:1051–1166. x–xi. 2007. View Article : Google Scholar : PubMed/NCBI
7	Vezali E, Elefsiniotis I, Mihas C, Konstantinou E and Saroglou G: Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related? J Gastroenterol Hepatol. 24:1024–1029. 2009. View Article : Google Scholar : PubMed/NCBI
8	Antonelli A, Ferri C, Pampana A, Fallahi P, Nesti C, Pasquini M, Marchi S and Ferrannini E: Thyroid disorders in chronic hepatitis C. Am J Med. 117:10–13. 2004. View Article : Google Scholar
9	Nair Kesavachandran C, Haamann F and Nienhaus A: Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One. 8:e553642013.
10	Danilovic DL, Mendes-Correa MC, Chammas MC, Zambrini H, Barros RK and Marui S: Thyroid disturbance related to chronic hepatitis C infection: role of CXCL10. Endocr J. 60:583–590. 2013. View Article : Google Scholar : PubMed/NCBI
11	Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P, Regnier D, Dreyfus G, Pradier C, Sadoul JL, et al: High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology. 18:253–257. 1993. View Article : Google Scholar : PubMed/NCBI
12	Rodríguez-Torres M, Ríos-Bedoya CF, Ortiz-Lasanta G, Marxuach-Cuétara AM and Jiménez-Rivera J: Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis. Ann Hepatol. 7:72–77. 2008.PubMed/NCBI
13	Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS and Weissman NJ: Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 291:228–238. 2004. View Article : Google Scholar : PubMed/NCBI
14	Khairy M, El-Raziky M, El-Akel W, Abdelbary MS, Khatab H, El-Kholy B, Esmat G and Mabrouk M: Serum autoantibodies positivity prevalence in patients with chronic HCV and impact on pegylated interferon and ribavirin treatment response. Liver Int. 33:1504–1509. 2013.PubMed/NCBI
15	Yang DH, Ho LJ and Lai JH: Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders. World J Gastroenterol. 20:2962–2970. 2014. View Article : Google Scholar : PubMed/NCBI
16	Oliveira-Filho AB, Sawada L, Pinto LC, Locks D, Bahia SL, Castro JA, Hermes RB, Brasil-Costa I, Amaral CE and Lemos JA: Epidemiological aspects of HCV infection in non-injecting drug users in the Brazilian state of Pará, eastern Amazon. Virol J. 11:382014.PubMed/NCBI
17	Singh P, Kaur R and Kaur A: Frequency distribution of Hepatitis C virus in different geographical regions of Punjab: Retrospective study from a tertiary care centre in North India. J Nat Sci Biol Med. 5:56–58. 2014. View Article : Google Scholar : PubMed/NCBI
18	Viazov S, Zibert A, Ramakrishnan K, Widell A, Cavicchini A, Schreier E and Roggendorf M: Typing of hepatitis C virus isolates by DNA enzyme immunoassay. J Virol Methods. 48:81–91. 1994. View Article : Google Scholar : PubMed/NCBI
19	Sibbing B and Nattermann J: Hepatitis C virus infection and genetic susceptibility to therapy. J Gastrointestin Liver Dis. 20:397–406. 2011.PubMed/NCBI
20	Zeuzem S, Berg T, Moeller B, Hinrichsen H, Mauss S, Wedemeyer H, Sarrazin C, Hueppe D, Zehnter E and Manns MP: Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat. 16:75–90. 2009. View Article : Google Scholar : PubMed/NCBI
21	Ploix C, Verber S, Chevallier - Queyron P, Ritter J, Bousset G, Monier JC and Fabien N: Hepatitis C virus infection is frequently associated with high titers of anti-thyroid antibodies. Int J Immunopathol Pharmacol. 12:121–126. 1999.PubMed/NCBI
22	Yang R, Shan Z, Li Y, Fan C, Li C and Teng W: Prevalence of thyroid autoantibodies in hepatitis C and hepatitis B infection in China. Intern Med. 50:811–815. 2011. View Article : Google Scholar : PubMed/NCBI
23	Danilovic DL, Mendes-Correa MC, Chammas MC, Zambrini H, Barros RK and Marui S: Thyroid disturbance related to chronic hepatitis C infection: role of CXCL10. Endocr J. 60:583–590. 2013. View Article : Google Scholar : PubMed/NCBI
24	Dalgard O, Bjøro K, Hellum K, Myrvang B, Bjøro T, Haug E and Bell H: Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy. J Intern Med. 251:400–406. 2002. View Article : Google Scholar : PubMed/NCBI
25	Friedrich-Rust M, Theobald J, Zeuzem S and Bojunga J: Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C. J Viral Hepat. 16:168–177. 2009. View Article : Google Scholar
26	Andrade LJ, Atta AM, D’Almeida Junior A and Paraná R: Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin - a review. Braz J Infect Dis. 12:144–148. 2008. View Article : Google Scholar : PubMed/NCBI
27	Chirico V, Antonio L, Vincenzo S, Luca N, Valeria F, Basilia P, Luciana R, Carmelo S and Teresa A: Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy. Eur J Endocrinol. 170:X32014. View Article : Google Scholar : PubMed/NCBI
28	Tao YL, Tang YF, Qiu JP, Cai XF, Shen XT, Wang YX and Zhao XT: Prevalence of hepatitis C infection among intravenous drug users in Shanghai. World J Gastroenterol. 19:5320–5325. 2013. View Article : Google Scholar : PubMed/NCBI
29	Hsieh MC, Yu ML, Chuang WL, Shin SJ, Dai CY, Chen SC, Lin ZY, Hsieh MY, Liu JF, Wang LY and Chang WY: Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrinol. 142:431–437. 2000. View Article : Google Scholar : PubMed/NCBI
30	Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP and Ladenson PW: Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 295:1033–1041. 2006. View Article : Google Scholar : PubMed/NCBI